ABN.AS: $40.75 ▲ 0.30 (0.74%)DSFIR.AS: $99.66 ▼ -0.99 (-0.98%)GMAB.CO: $2,487.00 ▲ 42.00 (1.72%)REP.MC: $29.21 ▼ -0.31 (-1.05%)SOON.SW: $267.80 ▲ 3.20 (1.21%)CRWD: $263.07 ▼ -11.97 (-4.35%)HPE: $70.13 ▼ -3.33 (-4.53%)AMD: $590.04 ▼ -18.06 (-2.97%)DELL: $574.99 ▼ -11.07 (-1.89%)PANW: $399.75 ▼ -19.03 (-4.54%)MRNA: $214.23 ▼ -10.77 (-4.79%)AAPL: $339.52 ▲ 2.88 (0.86%)AMZN: $259.82 ▼ -2.61 (-0.99%)MSFT: $539.81 ▲ 4.74 (0.89%)NVDA: $226.42 ▼ -2.86 (-1.25%)CIEN: $403.29 ▼ -46.48 (-10.34%)DDOG: $287.72 ▼ -5.54 (-1.89%)SNPS: $503.07 ▼ -6.92 (-1.36%)CAP.PA: $115.35 ▲ 0.30 (0.26%)TSCO.L: $511.00 ▲ 7.20 (1.43%)WKL.AS: $77.16 ▲ 2.16 (2.88%)

Company Details

PainReform Ltd.

PRFX - NASDAQ

Identifiants & Marche

Ticker PRFX
ISIN IL0011651580
CIK 0001801834
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare

Entreprise

Pays IL
Siege N/A
Fondee N/A
Site Web Lien

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.